Neurocognitive impairment in HIV-1-infected adults in Sub-Saharan Africa: A systematic review and meta-analysis

International Journal of Infectious Diseases

Volumn 17, Issue 10, 2013, Pages

  Habib, Abdulrazaq G ^a   Yakasai, Ahmad M ^a   Owolabi, Lukman F ^a   Ibrahim, Aliyu ^a   Habib, Zaharaddeen G ^b   Gudaji, Mustafa ^a   Karaye, Kamilu M ^a   Ibrahim, Daiyabu A ^a   Nashabaru, Ibrahim ^a  

^a BAYERO UNIVERSITY   (Nigeria)

^b Federal Neuropsychiatry Hospital   (Nigeria)

Author keywords

Africa; Antiretroviral therapy; Dementia; Human immunodeficiency virus; Neurocognitive impairment

Indexed keywords

ANTIRETROVIRUS AGENT;

AFRICA SOUTH OF THE SAHARA; ANTIVIRAL THERAPY; ATTRIBUTABLE RISK; CD4 LYMPHOCYTE COUNT; COGNITIVE DEFECT; DRUG UTILIZATION; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION RISK; LONGITUDINAL STUDY; META ANALYSIS; PREVALENCE; REVIEW; SYSTEMATIC REVIEW; UGANDA;

AFRICA; ANTIRETROVIRAL THERAPY; DEMENTIA; HUMAN IMMUNODEFICIENCY VIRUS; NEUROCOGNITIVE IMPAIRMENT;

ADULT; AFRICA SOUTH OF THE SAHARA; AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; HIV-1; HUMANS; OBSERVATIONAL STUDY AS TOPIC; PREVALENCE;

EID: 84883809199     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2013.06.011     Document Type: Review

References (76)

1. McArthur J.C., Haughey N., Gartner S., Conant K., Pardo C., Nath A., et al. Human immunodeficiency virus-associated dementia: an evolving disease. J Neurovirol 2003, 9:205-221.
2. Robertson K., Liner J., Hakim J., Sankale J.L., Grant I., Letendre S., et al. NeuroAIDS in Africa. J Neurovirol 2010, 16:189-202.
3. Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol 2002, 8(Suppl 2):115-121.
4. Turnbull O., Saling M.M., Kaplan-Solms K., Cohn R., Schoub B. Neuropsychological deficit in haemophiliacs with human immunodeficiency virus. J Neurol Neurosurg Psychiatry 1991, 54:175-177.
5. World Health Organization consultation on the neuropsychiatric aspects of HIV-1 infection. Geneva, 11-13 January 1990. AIDS 1990, 4:935-936.
6. Antinori A., Arendt G., Becker J.T., Brew B.J., Byrd D.A., Cherner M., et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007, 69:1789-1799.
7. Sacktor N.C., Wong M., Nakasujja N., Skolasky R.L., Selnes O.A., Musis S., et al. The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS 2005, 19:1367-1374.
8. Cysique L.A., Maruff P., Brew B.J. The neuropsychological profile of symptomatic AIDS and ADC patients in the pre-HAART era: a meta-analysis. J Int Neuropsychol Soc 2006, 12:368-382.
9. Joska J.A., Gouse H., Paul R.H., Stein D.J., Flisher A.J. Does highly active antiretroviral therapy improve neurocognitive function? A systematic review. J Neurovirol 2010, 16:101-114.
10. Stroup D.F., Berlin J.A., Morton S.C., Olkin I., Williamson G.D., Rennie D., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000, 283:2008-2012.
11. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009, 6:e1000097.
12. Downs S.H., Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998, 52:377-384.
13. Sankey S.S., Weissfeld L.A., Fine M.J., Kapoor W.N. An assessment of the use of the community correction for sparse data in meta-analysis. Commun Stat Simul Comput 1996, 25:1031-1056.
14. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
15. Tobias A. Assessing the influence of single study in the meta-analysis estimate (sb26). Stata Technical Bulletin 1999, 47:15-17.
16. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
17. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
18. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
19. Lau J., Ioannidis J.P., Terrin N., Schmid C.H., Olkin I. The case of the misleading funnel plot. BMJ 2006, 333:597-600.
20. Gordis L. Epidemiology 2009, Saunders Elsevier, Philadelphia, USA. 4th ed.
21. Thompson S.G., Higgins J.F. How should meta-regression analyses be undertaken and interpreted?. Stat Med 2002, 21:1559-1573. 10.1002/sim.1187.
22. UNAIDS 2012. Regional Fact Sheet 2012. Available at: (accessed June 30, 2012). http://www.unaids.org/en/regionscountries/regions/.
23. Perriens J.H., Mussa M., Luabeya M.K., Kayembe K., Luabeya M.K., Kapita B., et al. Neurological complications of HIV-1-seropositive internal medicine inpatients in Kinshasa, Zaire. J Acquir Immune Defic Syndr 1992, 5:333-340.
24. Maj M., Satz P., Janssen R., Zaudig M., Starace F., D'Elia, et al. WHO Neuropsychiatric AIDS Study, cross-sectional phase II. Neuropsychological and neurological findings. Arch Gen Psychiatry 1994, 51:51-61.
25. Sebit M.B., Tombe M., Siziya S., Balus S., Nkomo S.D., Maramba P. Prevalence of HIV/AIDS and psychiatric disorders and their related risk factors among adults in Epworth, Zimbabwe. East Afr Med J 2003, 80:503-512.
26. Odiase F., Ogunrin O., Ogunniyi A. Effect of progression of disease on cognitive performance in HIV/AIDS. J Natl Med Assoc 2006, 98:1260-1262.
27. Sacktor N., Nakasujja N., Skolasky R., Robertson K., Wong M., Musisi S., et al. Antiretroviral therapy improves cognitive impairment in HIV-positive individuals in Sub-Saharan Africa. Neurology 2006, 67:311-314.
28. Modi G., Hari K., Modi M., Mochan A. The frequency and profile of neurology in black South African HIV infected (clade C) patients-a hospital-based prospective audit. J Neurol Sci 2007, 254:60-64.
29. Salawu F.K., Bwala S.A., Wakil M.A., Bani B., Bukbuk D.N., Kida I. Cognitive function in HIV-seropositive Nigerians without AIDS. J Neurol Sci 2008, 267:142-146.
30. Wong M.H., Robertson K., Nakasujja N., Skolasky R., Musisi S., Katabira E., et al. Frequency of and risk factors for HIV dementia in an HIV clinic in Sub-Saharan Africa. Neurology 2007, 68:350-355.
31. McGrath N.M., Cooke G.S. Frequency of and risk factors for HIV dementia in an HIV clinic in Sub-Saharan Africa. Neurology 2007, 69:411-412. author reply 412-3.
32. Singh D., Sunpath H., John S., Eastham L., Gouden R. The utility of a rapid screening tool for depression and HIV dementia amongst patients with low CD4 counts-a preliminary report. Afr J Psychiatry (Johannesbg) 2008, 11:282-286.
33. Kvalsund M.P., Haworth A., Murman D.L., Velie E., Birbeck G.L. Closing gaps in antiretroviral therapy access: human immunodeficiency virus-associated dementia screening instruments for non-physician healthcare workers. Am J Trop Med Hyg 2009, 80:1054-1059.
34. Njamnshi A.K., Bissek A.C., Ongolo-Zogo P., Tabah E.N., Lekoubou A.Z., Yepnjio F.N., et al. Risk factors for HIV-associated neurocognitive disorders (HAND) in Sub-Saharan Africa: the case of Yaoundé, Cameroon. J Neurol Sci 2009, 285:149-153.
35. Ogunrin A.O., Emeka U.E., Francis A. Usefulness of the HIV Dementia Scale in Nigerian patients with HIV/AIDS. The Southern African Journal of HIV Medicine 2009, 10:38-43.
36. Sacktor N., Nakasujja N., Skolasky R.L., Rezapour M., Robertson K., Musisi S., et al. HIV subtype D is associated with dementia, compared with subtype A, in immunosuppressed individuals at risk of cognitive impairment in Kampala, Uganda. Clin Infect Dis 2009, 49:780-786.
37. Akena D.H., Musisi S., Kinyanda E. A comparison of the clinical features of depression in HIV-positive and HIV-negative patients in Uganda. Afr J Psychiatry (Johannesbg) 2010, 13:43-51.
38. Joska J.A., Combrinck M., Valcour V.G., Hoare J., Leisegang F., Mahne A.C., et al. Association between apolipoprotein E4 genotype and human immunodeficiency virus-associated dementia in younger adults starting antiretroviral therapy in South Africa. J Neurovirol 2010, 16:377-383.
39. Nakasujja N., Skolasky R.L., Musisi S., Allebeck P., Robertson K., Ronald A., et al. Depression symptoms and cognitive function among individuals with advanced HIV infection initiating HAART in Uganda. BMC Psychiatry 2010, 10:44.
40. Patel V.N., Mungwira R.G., Tarumbiswa T.F., Heikinheimo T., van Oosterhout J.J. High prevalence of suspected HIV-associated dementia in adult Malawian HIV patients. Int J STD AIDS 2010, 21:356-358.
41. Birbeck G.L., Kvalsund M.P., Byers P.A., Bradbury R., Mang'ombe C., Organek N., et al. Neuropsychiatric and socioeconomic status impact antiretroviral adherence and mortality in rural Zambia. Am J Trop Med Hyg 2011, 85:782-789.
42. Holguin A., Banda M., Willen E.J., Malama C., Chiyenu K.O., Mudenda V.C., et al. HIV-1 effects on neuropsychological performance in a resource-limited country, Zambia. AIDS Behav 2011, 15:1895-1901.
43. Joska J.A., Westgarth-Taylor J., Hoare J., Thomas K.G., Paul R., Myer L., et al. Validity of the International HIV Dementia Scale in South Africa. AIDS Patient Care STDS 2011, 25:95-101.
44. Joska J.A., Westgarth-Taylor J., Myer L., Hoare J., Thomas K.G., Combrinck M., et al. Characterization of HIV-associated neurocognitive disorders among individuals starting antiretroviral therapy in South Africa. AIDS Behav 2011, 15:1197-1203.
45. Royal W., Cherner M., Carr J., Habib A.G., Akomolafe A., Abimku A., et al. Clinical features and preliminary studies of virological correlates of neurocognitive impairment among HIV-infected individuals in Nigeria. J Neurovirol 2012, 18:191-199.
46. Robertson K., Kumwenda J., Supparatpinyo K., Jiang J.H., Evans S., Campbell T.B., et al. A multinational study of neurological performance in antiretroviral therapy-naive HIV-1-infected persons in diverse resource-constrained settings. J Neurovirol 2011, 17:438-447.
47. Belec L., Martin P.M., Vohito M.D., Gresenguet G., Tabo A., Georges A.J. Low prevalence of neuro-psychiatric clinical manifestations in Central African patients with acquired immune deficiency syndrome. Trans R Soc Trop Med Hyg 1989, 83:844-846.
48. Howlett W.P., Nkya W.M., Mmuni K.A., Missalek W.R. Neurological disorders in AIDS and HIV disease in the northern zone of Tanzania. AIDS 1989, 3:289-296.
49. Ogun A.S., Ojini F., Okubadejo N., Danesi M., Kolapo K., Osalusi B., et al. Pattern and outcome of neurological manifestations of HIV/AIDS. A review of 154 cases in a Nigerian University Teaching Hospital-a preliminary report. African Journal of Neurological Sciences 2005, 24:29-36.
50. Sall L., Salamon E., Allgulander C., Owe-Larsson B. Psychiatric symptoms and disorders in HIV infected mine workers in South Africa. A retrospective descriptive study of acute first admissions. Afr J Psychiatry (Johannesbg) 2009, 12:206-212.
51. Lawler K., Jeremiah K., Mosepele M., Ratcliffe S.J., Cherry C., Seloilwe E., et al. Neurobehavioral effects in HIV-positive individuals receiving highly active antiretroviral therapy (HAART) in Gaborone, Botswana. PLoS One 2011, 6:e17233.
52. Kanmogne G.D., Kuate C.T., Cysique L.A., Fonsah J.Y., Eta S., Doh R., et al. HIV-associated neurocognitive disorders in Sub-Saharan Africa: a pilot study in Cameroon. BMC Neurol 2010, 10:60.
53. Lawler K., Mosepele M., Ratcliffe S., Seloilwe E., Steele K., Nthobatsang R., et al. Neurocognitive impairment among HIV-positive individuals in Botswana: a pilot study. J Int AIDS Soc 2010, 13:15.
54. Breuer E., Stoloff K., Myer L., Seedat S., Stein D.J., Joska J. Reliability of the lay adherence counsellor administered Substance Abuse and Mental Illness Symptoms Screener (SAMISS) and the International HIV Dementia Scale (IHDS) in a primary care HIV clinic in Cape Town, South Africa. AIDS Behav 2012, 16(6):1464-1471.
55. Nakimuli-Mpungu E., Musisi S., Katabira E., Nachega J., Bass J. Prevalence and factors associated with depressive disorders in an HIV-positive rural patient population in southern Uganda. J Affect Disord 2011, 135:160-167.
56. Robbins R.N., Remien R.H., Mellins C.A., Joska J.A., Stein D.J. Screening for HIV-associated dementia in South Africa: potentials and pitfalls of task-shifting. AIDS Patient Care STDS 2011, 25:587-593.
57. Imam I. Neurological manifestations of HIV infection in Nigerians. African Journal of AIDS Research 2007, 6:187-192.
58. Joska J.A., Fincham D.S., Stein D.J., Paul R.H., Seedat S. Clinical correlates of HIV-associated neurocognitive disorders in South Africa. AIDS Behav 2010, 14:371-378.
59. Kinyanda E., Hoskins S., Nakku J., Nawaz S., Patel V. Prevalence and risk factors of major depressive disorder in HIV/AIDS as seen in semi-urban Entebbe district, Uganda. BMC Psychiatry 2011, 11:205.
60. Sebit M.B. Neuropsychiatric HIV-1 infection study: in Kenya and Zaire cross-sectional phase I and II. Cent Afr J Med 1995, 41:315-322.
61. Odiase F.E., Ogunrin O.A., Ogunniyi A.A. Memory performance in HIV/AIDS-a prospective case control study. Can J Neurol Sci 2007, 34:154-159.
62. Ganasen K.A., Fincham D., Smit J., Seedat S., Stein D. Utility of the HIV Dementia Scale (HDS) in identifying HIV dementia in a South African sample. J Neurol Sci 2008, 269:62-64.
63. Njamnshi A.K., Djientcheu Vde P., Fonsah J.Y., Yepnjio F.N., Njamnshi D.M., Muna W.E. The International HIV Dementia Scale is a useful screening tool for HIV-associated dementia/cognitive impairment in HIV-infected adults in Yaoundé, Cameroon. J Acquir Immune Defic Syndr 2008, 49:393-397.
64. Oshinaike O.O., Okubadejo N.U., Ojini F.I., Danesi M.A. The clinical spectrum of neurological manifestations in HIV/AIDS patients on HAART at the Lagos University Teaching Hospital, Lagos, Nigeria. Nig Q J Hosp Med 2009, 19:181-185.
65. Clifford D.B., Mitike M.T., Mekonnen Y., Zhang J., Zenebe G., Melaku Z., et al. Neurological evaluation of untreated human immunodeficiency virus infected adults in Ethiopia. J Neurovirol 2007, 13:67-72.
66. Sacktor N., Nakasujja N., Skolasky R.L., Robertson K., Musis S., Ronald A., et al. Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda. Neurology 2009, 72:165-170.
67. ONE International. HIV/AIDS; 2011. Available at: (accessed June 28, 2012). http://www.one.org/international/issuebrief/1584.
68. Gisslen M., Price R.W., Nilsson S. The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence?. BMC Infect Dis 2011, 11:356.
69. John Hopkins Medical Institutions. HIV dementia alarmingly high in Africa. Science Daily; January 29, 2007. Available at: (accessed June 23, 2012). http://www.sciencedaily.com/releases/2007/01/070129171855.htm.
70. McArthur J.C., Hoover D.R., Bacellar H., Miller E.N., Cohen B.A., Becker J.T., et al. Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology 1993, 43:2245-2252.
71. Obiabo Y.O., Ogunrin O.A., Ogun A.S. Effects of highly active antiretroviral therapy on cognitive functions in severely immune-compromised HIV-seropositive patients. J Neurol Sci 2012, 313:115-122.
72. Nath A., Schiess N., Venkatesan A., Rumbaugh J., Sacktor N., McArthur J. Evolution of HIV dementia with HIV infection. Int Rev Psychiatry 2008, 20:25-31.
73. Ngandu T., von Strauss E., Helkala E.L., Winblad B., Nissinen A., Tuomilehto J., et al. Education and dementia: what lies behind the association?. Neurology 2007, 69:1442-1450.
74. Sacktor N., Nakasujja N., Robertson K., Clifford D.B. HIV-associated cognitive impairment in Sub-Saharan Africa-the potential effect of clade diversity. Nat Clin Pract Neurol 2007, 3:436-443.
75. Choi Y., Townend J., Vincent T., Zaidi I., Sarge-Njie R., Jaye A., et al. Neurologic manifestations of human immunodeficiency virus-2: dementia, myelopathy, and neuropathy in West Africa. J Neurovirol 2011, 17:166-175.
76. Dickersin K., Berlin J.A. Meta-analysis: state-of-the-science. Epidemiol Rev 1992, 14:154-176.